UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 2, 2011
CALIPER LIFE SCIENCES, INC.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
001-32976 |
|
33-0675808 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
68 Elm Street, Hopkinton, Massachusetts |
|
01748 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
(508) 435-9500
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On August 2, 2011, Caliper Life Sciences, Inc. issued a press release announcing financial results for its second quarter ended June 30, 2011. The press release is attached to this report as Exhibit 99.1.
The information in this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Caliper, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits
|
EXHIBIT NO. |
|
EXHIBIT |
|
|
|
|
|
99.1 |
|
Press Release entitled “Caliper Life Sciences Reports Second Quarter 2011 Results.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
CALIPER LIFE SCIENCES, INC. | |
|
|
|
|
|
August 2, 2011 |
By: |
/s/ Peter F. McAree |
|
|
|
Peter F. McAree |
|
|
|
Senior Vice President and CFO |
EXHIBIT 99.1
For Immediate Release
Caliper Life Sciences Reports Second Quarter 2011 Results
- 23% Organic Revenue Growth and 84% EBITDA Improvement Compared to Prior Year Q2 -
- Rapid Growth of Next Generation Sequencing (“NGS”) Markets Drives Adoption of Caliper’s
Analytical and Preparative NGS Platforms for Sample Preparation and Process Control -
- LabChip® Dx Receives In Vitro Diagnostic Medical Device Approval (“CE IVD”) in Europe -
- Full Year Financial Outlook Increased -
HOPKINTON, Mass., August 2, 2011 — Caliper Life Sciences, Inc. (NASDAQ: CALP) today reported its financial results for the second quarter ended June 30, 2011. Second quarter revenue increased to $38.3 million, or 32%, from $29.1 million in the same period of 2010. Organic revenue, which excludes the effects of acquisitions, divestitures and currency changes, grew by 23% over the second quarter of 2010 (24% on a year-to-date basis). Caliper reported a second quarter net loss of $0.06 per share compared to net income per share of $0.18 in the same period of 2010, which resulted from the gain on the divestiture of Caliper’s former specialty products business. Caliper had second quarter non-GAAP adjusted earnings of $1.0 million, or $0.02 per diluted share compared to break-even non-GAAP adjusted earnings per share in the same period of 2010, as well as EBITDA of $2.7 million in the second quarter, which was an 84% improvement over the second quarter of 2010.
Please refer to the tables included under “Reconciliation of GAAP to Non-GAAP Financial Measures” for itemized reconciliations between GAAP and non-GAAP financial measures appearing in this release.
Among recent business highlights:
· Caliper announced on July 26 that its LabChip Dx instrument has achieved CE IVD registration which allows the LabChip Dx to be used to process clinical patient samples in Europe. The LabChip Dx currently runs tests from the Seeplex® menu of diagnostic assays from Seegene Inc. and is marketed outside of the United States through Seegene’s international distributor network.
· Caliper announced new collaborations during the second quarter for NGS sample preparation and quality control platforms with Roche Nimblegen, EdgeBio and The Genome Analysis Centre, involving the use of Caliper’s NGS platform solutions, including the Sciclone® NGS workstation and the LabChip GX and LabChip XT instruments.
· Caliper completed the integration and transfer of Cambridge Research & Instrumentation, Inc.’s (CRi) manufacturing operations from Woburn, Mass. to its Hopkinton, Mass.
headquarters, resulting in closure of the Woburn facility in the second quarter. The shutdown occurred one quarter earlier than initially projected.
· Caliper hosted its 2011 annual Caliper Owners Group (COG 2011) meeting on May 17 and 18 at its Hopkinton headquarters. This thought-leadership conference brought together leaders in life sciences research, drug discovery, and diagnostics to discuss the technologies and discoveries that are transforming the detection and treatment of disease, and making personalized medicine a reality. More than 350 customers attended the event, which featured 45 presentations from researchers representing life sciences companies, universities and other institutions.
“We are pleased with our second quarter financial results and the strategic progress we made in the quarter,” commented Kevin Hrusovsky, President and CEO of Caliper Life Sciences. “We had a robust quarter in our Research business unit due to strong ongoing adoption of our NGS sample preparation solutions, molecular diagnostics penetration with the LabChip Dx, and continued LabChip GX adoption driven by biotherapeutic and vaccine development. In addition, our recently announced CE IVD approval opens up new market opportunities in Europe for the LabChip Dx, and enhances our clinical diagnostics long-term growth potential. We are particularly pleased that our strategic transformation designed to commercialize disruptive technologies for revolutionizing and personalizing medicine is gaining momentum and traction in all target markets,” added Hrusovsky.
Analysis of Second Quarter 2011 Results
· GAAP revenue increased 32% in the second quarter of 2011 compared to the same period in 2010. Non-GAAP revenues grew 37% in the second quarter of 2011 compared to the same period of 2010, comprised of 23% organic growth, 10% acquisition-driven growth and 4% favorable currency benefit. Non-GAAP revenue growth for each of Caliper’s three principal business units was as follows:
– Research revenue grew 52%, comprised of microfluidics (LabChip) and automation product line growth of 51% and 53%, respectively. Both LabChip and automation growth was driven by end market demand for Caliper’s analytical and preparative NGS sample preparation and quality control platforms. LabChip revenues also benefitted from increasing market adoption of Caliper’s LabChip Dx instrument for multiplex molecular diagnostic analysis, for which CE IVD approval was recently received, and an increase in microfluidics intellectual property license revenue.
– Imaging revenue grew 23% driven primarily by tissue imaging products added to Caliper’s imaging platform capabilities as a result of its acquisition of CRi in December 2010. In vivo imaging revenues were relatively flat quarter over quarter due primarily to some delayed funding situations in certain academic and commercial accounts, and to a lesser extent to the product mix sold during the quarter.
– Services (CDAS) revenue grew 82% primarily attributable to revenues from CDAS’ contract with the Environmental Protection Agency (“EPA”) under the EPA’s ToxCast™ screening program.
· Total gross margin was relatively flat at 52% compared to the second quarter of 2010 due to unfavorable changes in revenue and sales channel mix which partially offset the incremental contribution that overall higher revenues had upon gross margin.
· Operating expenses (research and development, and selling, general and administrative costs) increased 27% to $19.1 million, from $15.0 million in the same period in 2010. Approximately one-half of the increase was attributable to incremental operating expenses incurred as a result of the addition of CRi’s operations. The remainder of the expense increase resulted primarily from increased investment in sales and marketing efforts and increased legal expenses due to litigation which was ongoing during the second quarter.
· Caliper recorded a restructuring charge of approximately $1.3 million in the second quarter related to the closure of the CRi facility in Woburn, Mass. Caliper also recorded a charge of approximately $1.1 million, in addition to scheduled amortization, to write-off certain in-process research and development assets deemed to no longer have value.
2011 Guidance
Caliper is currently projecting 2011 full year GAAP revenue between $146 and $152 million. In addition, the Company estimates third quarter revenues in the range of $33 to $36 million. Caliper will provide further details on its business outlook during the conference call today.
Use of Non-GAAP Financial Measures
Caliper supplements its GAAP financial reporting with certain non-GAAP financial measures. Reconciliations of Caliper’s GAAP to non-GAAP revenue and earnings per share are provided at the end of this release under “Reconciliation of GAAP to Non-GAAP Financial Measures.”
Certain revenue growth percentages in this press release are derived from non-GAAP revenues which exclude the impact of revenue from product and services lines which were divested in the second quarter of 2010. Caliper believes that providing this additional information enhances investors’ understanding of the financial performance of the Company’s operations and increases the comparability of its current financial statements to prior periods.
Caliper will discuss its second quarter results in a conference call to be held today at 5:00 pm ET. Participants should call 888.680.0860 five to ten minutes prior to the call and use the participant passcode of 39159073. International callers can access the call by dialing 617.213.4852 and entering the same passcode. You may also pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=P8J9TBCRA.
A live webcast of the call can be accessed at www.earnings.com or on the Caliper website at www.caliperLS.com in the Events section of the Investor Relations page. A webcast replay of the call will remain available until Caliper’s earnings call for the third quarter of 2011.
Telephone replays of the conference call will be available approximately two hours after the completion of the call. To access a telephone playback of the proceedings from August 2 to August 9, dial 888.286.8010 and passcode 70172145. International callers can access the playback by dialing
617.801.6888 and using the same participant passcode.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
The statements in this press release regarding future events, including Caliper’s 2011 full year and third quarter GAAP revenue projections, are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including that Caliper’s expectations regarding demand for its products and services may not materialize if capital spending by Caliper’s customers declines, if customers do not purchase the recently acquired CRi products as rapidly as Caliper believes that they will, or if competitors introduce new competitive products, or if Caliper is unable to convince potential customers regarding the superior performance of its microfluidic and imaging systems and products. Further information on risks faced by Caliper are detailed under the caption “Risks Related To Our Business” in Caliper’s Annual Report on Form 10-K for the year ended December 31, 2010. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release or the conference call.
NOTE: Caliper, LabChip and Sciclone are registered trademarks of Caliper Life Sciences, Inc. CRi is a registered trademark of Cambridge Research & Instrumentation, Inc., a wholly owned subsidiary of Caliper Life Sciences, Inc. ToxCast is a trademark of the Environmental Protection Agency. Seeplex is a registered trademark of Seegene, Inc.
Contacts:
Peter F. McAree
SVP and Chief Financial Officer
774.278.2215
Media Contact:
Benjamin Navon/Kristin Villiotte
Schwartz Communications
781.684.0770
CALIPER LIFE SCIENCES, INC.
SELECTED FINANCIAL INFORMATION
(unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
June 30, |
|
June 30, |
| ||||||||
|
|
|
2011 |
|
2010 |
|
2011 |
|
2010 |
| ||||
|
Revenue: |
|
|
|
|
|
|
|
|
| ||||
|
Product revenue |
|
$ |
26,711 |
|
$ |
20,486 |
|
$ |
51,653 |
|
$ |
40,854 |
|
|
Service revenue |
|
6,823 |
|
5,343 |
|
14,055 |
|
10,424 |
| ||||
|
License fees and contract revenue |
|
4,807 |
|
3,221 |
|
8,453 |
|
6,424 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Total revenue |
|
38,341 |
|
29,050 |
|
74,161 |
|
57,702 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Costs and expenses: |
|
|
|
|
|
|
|
|
| ||||
|
Cost of product revenue |
|
13,602 |
|
10,101 |
|
26,497 |
|
20,396 |
| ||||
|
Cost of service revenue |
|
3,916 |
|
3,317 |
|
7,612 |
|
6,507 |
| ||||
|
Cost of license revenue |
|
971 |
|
521 |
|
1,616 |
|
926 |
| ||||
|
Research and development |
|
5,510 |
|
4,299 |
|
10,902 |
|
8,646 |
| ||||
|
Selling, general and administrative |
|
13,542 |
|
10,745 |
|
27,262 |
|
21,604 |
| ||||
|
Amortization of intangible assets |
|
2,503 |
|
1,226 |
|
3,944 |
|
2,480 |
| ||||
|
Restructuring charges, net |
|
1,399 |
|
603 |
|
2,263 |
|
634 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Total costs and expenses |
|
41,443 |
|
30,812 |
|
80,096 |
|
61,193 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Operating loss |
|
(3,102 |
) |
(1,762 |
) |
(5,935 |
) |
(3,491 |
) | ||||
|
Interest expense, net |
|
(50 |
) |
(72 |
) |
(85 |
) |
(202 |
) | ||||
|
Gain on divestitures |
|
— |
|
11,424 |
|
— |
|
11,424 |
| ||||
|
Other income (expense), net |
|
91 |
|
(37 |
) |
403 |
|
(389 |
) | ||||
|
Provision for income taxes |
|
(178 |
) |
(316 |
) |
(217 |
) |
(323 |
) | ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Net income (loss) |
|
$ |
(3,239 |
) |
$ |
9,237 |
|
$ |
(5,834 |
) |
$ |
7,019 |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
Net income (loss) per share, basic |
|
$ |
(0.06 |
) |
$ |
0.18 |
|
$ |
(0.11 |
) |
$ |
0.14 |
|
|
Net income (loss) per share, diluted |
|
$ |
(0.06 |
) |
$ |
0.18 |
|
$ |
(0.11 |
) |
$ |
0.14 |
|
|
Shares used in computing net income (loss) per common share, basic |
|
52,417 |
|
50,070 |
|
52,236 |
|
49,776 |
| ||||
|
Shares used in computing net income (loss) per common share, diluted |
|
52,417 |
|
52,002 |
|
52,236 |
|
51,812 |
| ||||
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Non-GAAP Earnings and Earnings per Share (see explanation of adjustments below)(in thousands except per share data)
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
June 30, |
|
June 30, |
| ||||||||
|
|
|
2011 |
|
2010 |
|
2011 |
|
2010 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
GAAP income (loss) |
|
$ |
(3,239 |
) |
$ |
9,237 |
|
$ |
(5,834 |
) |
$ |
7,019 |
|
|
GAAP EPS - Basic |
|
$ |
(0.06 |
) |
$ |
0.18 |
|
$ |
(0.11 |
) |
$ |
0.14 |
|
|
Adjustments: |
|
|
|
|
|
|
|
|
| ||||
|
Acquisition related intangible amortization (1) |
|
$ |
2,503 |
|
$ |
1,226 |
|
$ |
3,944 |
|
$ |
2,480 |
|
|
Restructuring and severance costs (2) |
|
1,399 |
|
603 |
|
2,263 |
|
634 |
| ||||
|
Purchase accounting and acquisition related costs (3) |
|
226 |
|
— |
|
844 |
|
— |
| ||||
|
Gain on divestiture of product lines (4) |
|
— |
|
(11,424 |
) |
— |
|
(11,424 |
) | ||||
|
Taxes related to divestiture gain(4) |
|
— |
|
300 |
|
— |
|
300 |
| ||||
|
Total Adjustments |
|
$ |
4,128 |
|
$ |
(9,295 |
) |
$ |
7,051 |
|
$ |
(8,010 |
) |
|
|
|
|
|
|
|
|
|
|
| ||||
|
Per share effect of adjustments, basic |
|
$ |
0.08 |
|
$ |
(0.19 |
) |
$ |
0.13 |
|
$ |
(0.16 |
) |
|
Non-GAAP adjusted earnings (loss) |
|
$ |
889 |
|
$ |
(58 |
) |
$ |
1,217 |
|
$ |
(991 |
) |
|
Non-GAAP adjusted earnings (loss) per share, basic and diluted |
|
$ |
0.02 |
|
$ |
(0.00 |
) |
$ |
0.02 |
|
$ |
(0.02 |
) |
|
|
|
|
|
|
|
|
|
|
| ||||
|
Shares used in computing non-GAAP adjusted earnings (loss) per share, basic |
|
52,417 |
|
50,070 |
|
52,236 |
|
49,776 |
| ||||
|
Shares used in computing non-GAAP adjusted earnings (loss) per share, diluted |
|
56,606 |
|
52,002 |
|
56,097 |
|
51,812 |
| ||||
We use the term “adjusted earnings per share” or “adjusted EPS” to refer to GAAP earnings per share excluding amortization of intangible assets, impairment charges and restructuring and severance costs. Adjusted earnings per share is calculated by subtracting the total per share effect of these adjustments from GAAP EPS.
The adjustments are as follows:
1) We exclude amortization of intangible assets from this measure because intangible asset amortization charges do not represent what our management believes are the costs of developing, producing, supporting and selling our products and the costs to support our internal operating structure.
2) We exclude restructuring and severance costs from this measure because they tend to occur as a result of specific events such as acquisitions, divestitures, repositioning our business or other unusual events that could make comparisons of long-range trends difficult and are not reflective of our internal investments and the costs to support our operating structure.
3) We exclude purchase accounting adjustments and acquisition related costs from this measure because they occur as a result of specific events and are not reflective of our internal investments and the costs to support our operating structure. The costs within 2011 relate to CRi and consist of purchase accounting adjustments to value acquired inventory at fair value as well as a charge to terminate a CRi distributor relationship.
4) We exclude the net gain related to divestitures of product and service lines from this measure because they tend to occur as a result of specific events and also do not represent what our management and our investors believe are the costs of developing, producing, supporting and selling our products and the costs to support our internal operating structure.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited, continued)
Non-GAAP Revenues (in thousands) for the Three Months Ended June 30, 2011
|
|
|
GAAP |
|
Non-GAAP |
|
Non-GAAP |
|
GAAP |
|
Non-GAAP |
| ||||||
|
|
|
2011 |
|
2010 |
|
2010 |
|
2010 |
|
% Chg. |
|
% Chg. |
| ||||
|
Imaging |
|
$ |
18,206 |
|
$ |
14,826 |
|
$ |
— |
|
$ |
14,826 |
|
23 |
% |
23 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
LabChip |
|
11,183 |
|
7,412 |
|
— |
|
7,412 |
|
51 |
% |
51 |
% | ||||
|
Automation |
|
7,135 |
|
5,811 |
|
(1,152 |
) |
4,659 |
|
23 |
% |
53 |
% | ||||
|
Research |
|
18,318 |
|
13,223 |
|
(1,152 |
) |
12,071 |
|
39 |
% |
52 |
% | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
Services (CDAS) |
|
1,817 |
|
1,001 |
|
— |
|
1,001 |
|
82 |
% |
82 |
% | ||||
|
Total revenue |
|
$ |
38,341 |
|
$ |
29,050 |
|
$ |
(1,152 |
) |
$ |
27,898 |
|
32 |
% |
37 |
% |
Non-GAAP Revenues (in thousands) for the Six Months Ended June 30, 2011
|
|
|
GAAP |
|
Non-GAAP |
|
Non-GAAP |
|
GAAP |
|
Non-GAAP |
| ||||||
|
|
|
2011 |
|
2010 |
|
2010 |
|
2010 |
|
% Chg. |
|
% Chg. |
| ||||
|
Imaging |
|
$ |
37,607 |
|
$ |
28,291 |
|
$ |
— |
|
$ |
28,291 |
|
33 |
% |
33 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
LabChip |
|
20,013 |
|
14,182 |
|
— |
|
14,182 |
|
41 |
% |
41 |
% | ||||
|
Automation |
|
12,464 |
|
13,060 |
|
(3,610 |
) |
9,450 |
|
(5 |
)% |
32 |
% | ||||
|
Research |
|
32,477 |
|
27,242 |
|
(3,610 |
) |
23,632 |
|
19 |
% |
37 |
% | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
Services (CDAS) |
|
4,077 |
|
2,169 |
|
— |
|
2,169 |
|
88 |
% |
88 |
% | ||||
|
Total revenue |
|
$ |
74,161 |
|
$ |
57,702 |
|
$ |
(3,610 |
) |
$ |
54,092 |
|
29 |
% |
37 |
% |
(1) For purposes of comparing growth rates for each of the three principal product and service groups within of our business, the above non-GAAP table reconciliations exclude revenues related to the TurboVap and RapidTrace product lines divested in May 2010.
(2) Currency effects contributed to the above Research growth rates by 7% and 4% and the above Imaging growth rates by 3% and 2% during the three and six months ended June 30, 2011, respectively.
EBITDA (in thousands)
We use the term “EBITDA” to refer to GAAP earnings excluding interest, depreciation, amortization, non-cash stock compensation and other special items (e.g., restructuring charges). The following is a reconciliation of this Non-GAAP measure:
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
|
June 30, |
|
June 30, |
| ||||||||
|
|
|
2011 |
|
2010 |
|
2011 |
|
2010 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
GAAP Operating Loss |
|
$ |
(3,102 |
) |
$ |
(1,762 |
) |
$ |
(5,935 |
) |
$ |
(3,491 |
) |
|
Depreciation and amortization |
|
3,169 |
|
1,812 |
|
5,265 |
|
3,708 |
| ||||
|
Non-cash stock compensation |
|
959 |
|
790 |
|
1,948 |
|
1,802 |
| ||||
|
Purchase accounting and acquisition related costs |
|
226 |
|
— |
|
844 |
|
— |
| ||||
|
Restructuring and severance charges |
|
1,399 |
|
603 |
|
2,263 |
|
634 |
| ||||
|
EBITDA (Non-GAAP) |
|
$ |
2,651 |
|
$ |
1,443 |
|
$ |
4,385 |
|
$ |
2,653 |
|
CALIPER LIFE SCIENCES, INC.
SELECTED FINANCIAL INFORMATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
|
|
|
June 30, |
|
December 31, |
| ||
|
|
|
2011 |
|
2010 |
| ||
|
|
|
(unaudited) |
|
* |
| ||
|
Assets |
|
|
|
|
| ||
|
Current assets: |
|
|
|
|
| ||
|
Cash, cash equivalents and marketable securities |
|
$ |
34,330 |
|
$ |
34,846 |
|
|
Accounts receivable, net |
|
25,939 |
|
26,544 |
| ||
|
Inventories |
|
15,358 |
|
14,004 |
| ||
|
Other current assets |
|
3,863 |
|
2,916 |
| ||
|
|
|
|
|
|
| ||
|
Total current assets |
|
79,490 |
|
78,310 |
| ||
|
Property and equipment, net |
|
9,810 |
|
9,765 |
| ||
|
Intangible assets, net |
|
23,853 |
|
27,797 |
| ||
|
Goodwill |
|
27,958 |
|
27,958 |
| ||
|
Other assets |
|
631 |
|
592 |
| ||
|
|
|
|
|
|
| ||
|
Total assets |
|
$ |
141,742 |
|
$ |
144,422 |
|
|
|
|
|
|
|
| ||
|
Liabilities and stockholders’ equity |
|
|
|
|
| ||
|
Current liabilities |
|
$ |
42,099 |
|
$ |
42,404 |
|
|
Other long-term obligations |
|
11,661 |
|
11,330 |
| ||
|
Stockholders’ equity |
|
87,982 |
|
90,688 |
| ||
|
|
|
|
|
|
| ||
|
Total liabilities and stockholders’ equity |
|
$ |
141,742 |
|
$ |
144,422 |
|
*Note: Derived from audited financial statements for the year ended December 31, 2010.
###